Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus ...

Patients across the United States now receive lab results on their phones and patient portals the same day those results are ...

Hims & Hers' stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Click to learn more.

AI-driven drug discovery, using LLMs and diffusion models, has improved drug design and reduced timelines. Although promising ...

As instruments grow faster, leaders say clinical impact will depend on trust, standards, data, and assays built for real ...

The startup is focused on developing evidence-based natural and synthetic therapeutics for conditions such as psoriasis, ...

Large language models (LLMs) are rapidly being integrated into clinical workflows, supporting tasks such as diagnosis ...

Nova Scotia's new clinical information system, known as One Person One Record, is now live at the IWK Health Centre and in ...

Health First labs on the Space Coast are integrating artificial intelligence, seeing the process of results being expedited.

Mass General Brigham, Mount Sinai and Baptist Health South Florida leaders explain how they vet clinical AI tools — and why the OpenEvidence dispute is mostly noise.

One of the biggest themes for ATS this year is the dramatically growing role of AI in all aspects of pulmonary disease, critical illness, and sleep disorders.

On National Doctor’s Day 2026, doctors claim that while AI is transforming healthcare, symptom checkers and self-diagnosis ...